Jonathan Goldman serves as Executive at Avalo Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Jonathan Goldman has executed 3 insider transactions totaling $163.0K, demonstrating a bearish approach to their equity position. Their most recent transaction on Nov 14, 2025 involved selling 3,167 shares valued at $45.3K.
Jonathan Goldman currently holds 8,200 shares of Avalo Therapeutics, Inc. (AVTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Jonathan Goldman has been a net seller of AVTX stock. They have purchased $0 and sold $163.0K worth of shares.
Jonathan Goldman's most recent insider trade was on Nov 14, 2025, when they sold 3,167 shares at $14.30 per share.
Get notified when new Form 4 filings are submitted
| $9.88 |
| Discretionary |
| Nov 14, 2025 | AVTX | $117.7K | Sale | 8,200 | $14.35 | Discretionary |